SB 332235

Research use only, not for human use.

A potent, selective and competitive CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with pKi of 8.92.

A potent, selective and competitive CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with pKi of 8.92; inhibits N-Ac-PGP- and CXCL1-induced neutrophil influx and the increased pulmonary tissue MPO levels in micelung tissue homogenates; effectively inhibits smoke-induced inflammatory and mucus hypersecretory changes in rat lung; also attenuates microglial inflammatory reactivity induced by Aβ1-42 intrahippocampal injection in animal model of Alzheimer’s disease.

SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines. Cell Viability Assay Cell Line:AML cell Concentration:1, 10, 100 μM Incubation Time:48 hours Result:Led to a dose-dependent decrease in proliferation in all cell lines.

SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees.SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis. Animal Model:Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)Dosage:10, 25 mg/kg Administration:P.o.; twice a day for 14 days Result:Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.

SB332235 | SB-332235

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

——

——

276702-15-9

410.66

C13H10Cl3N3O4S

>98% (HPLC)

——

ClC1=CC=CC(NC(NC2=C(O)C(S(=O)(N)=O)=C(Cl)C=C2)=O)=C1Cl

6-Chloro-3-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-hydroxybenzenesulfonamide

(-20℃)

With Ice Pack

≥ 2 years